Preventing Alzheimer’s

- Recognizing Alzheimer’s disease before it damages the brain enhances changes of successful treatment and increases the quality of life of the patient -

The baseline

•Every year ~10.000.000 new Alzheimer’s casesworldwide

•No easy way of diagnosing early Alzheimer’s

•No effective treatment

The problem

•Research focus on genetic risk factors (<5% ofall cases)

•Research focus on patients with

irreversible brain damage

•Disproportional little focus on

non-genetic risk factors (> 95% of all cases)

The solution

•A simple, cost-effective diagnostic test usingblood samples

•A test using human-relevant biomarkers forprocesses triggered by non-genetic risk factors

•Biomarkers for processes activated before anysignificant irreversible brain damage

Proprietary technology

•Domain:• Biomarker-based in vitro tools for preventive medicine

•Proprietary products for three high impactpathologies:

• Immunosuppression

• Cancer

• Neurodegeneration

Market validation

• ~10.000.000 newcases every yearworldwide

•Worldwide demandfor a simple, cost-effective and non-invasive solution

~10 million new

diagnosis per year

Market size

Delivering a robust pipeline of Alzheimer’s

therapeutics

About 30% accessible for the blood test (33,000 m€)

About 10% accessible for the blood test (340 m€/year)

The product(1) Liquid biopsy Advantages over traditional tissue-specific biopsy- Quick and easy to obtain,- Minimal pain and risk, - Minimally invasive

(2) Enrichment from plasma/serum of circulating

microRNAs

(3) Simple testing device carrying the ToxGenSolutions Alzheimer’s microRNA biomarker profile- Biosensor device for microRNA are available for other diseases,- Easy to use,- Low costs

(4) Read-out

Screening of individuals >60

years of age

Diagnosis, staging, Prognosis

Therapy selection (Response and

follow-up)

Monitoring(Disease evolution following

therapy)

Impact on clinical care

The business

~10 million new

diagnosis per year

€2,600 per sampleEurope

~2.45,000 new diagnosis per year

North America~475,000 new

diagnosis per year

9-10 m€

Full growth potential

Focus segments until 2024

Pricing based on current average costs without

scanning + 20%

Net profit by 2025 (EU+USA)

(Target: 20,000 tests)

Worldwide

single €125,000 fee and 5-7% royalties per year

(~5,000 test per licensee)

~13 m€

Net profit by 2025: (Target: 10 licences)

Net profit by 2030

(Target: 10% of the global market)

400 m€

The financial plan2015 2021 2022 2023 2024 2025 2026

(2)30.11.2015

Raised: €75,000 (Knowledge Transfer Funds preseed loan)

(4)01.01.2018

Raised: €540,000EFRO funding: €356,000

3RsMC ApS: €94,000ToxGenSolutions: €90,000

20202018 201920172016 2027 2028 2029 2030

(1) 22.05.2015

TGS established; Oxfordlaan 70,

Maastricht

(3)21.03.2017

Raised: €25,000 (3RsMC ApS Loan)

(6)01.01.2026

New capital to co-finance new premises

(5)01.01.2020

Raised: €350,000 (12.02.2019)

Target: €4,500,000 (31.12.2019)

Success criteria:- 10% of the global market- Net profit: 400 m€

Success criteria:- Anchored in EU and USA diagnositcs market- Net profit: 20 m€

5 year investment - Increasing capacity

- Scientific personnel € 1,200,000- Equipment and specialized material € 1,600,000- Integration of the product in the biosensor device € 600,000

- Strenghtning outreach to the market- Business development/Commercial personnel: € 700,000- Commercial material/activities € 400,000

Market adoption

Events (Presentations + exhibitions)

• Annual congress on Neurology and Neuroscience

• World Congress on Alzheimers Disease and Dementia

• World Congress on Neurology and Neuroscience

• International Conference on Neurology and Mental Disorders

• Alzheimer’s Disease and Dementia Conference

• European Dementia Conference

• World Congress on Advances and Innovations in Dementia

• International Conference on Neurology and Cognitive Neurosciences

Industrial PartnershipsDiagnostics industry

✓Firalis

✓reMYND

✓ Icometrix

❑ ...

Pharma/Biotech industry

❑ Janssens Pharmaceuticals

❑ Roche

❑ …

CompetitionNon-invasive

Invasive

Dementia

No irreversible

brain damage

Mild cognitive

impairment

CeXGat

Lumipulse® G NeuroAssay(FujiRebio)

Tau-test(Brigham and Women’s Hospital Boston, (USA))

NfL-test(Washington University School of Medicine

(USA) and German Center for Neurodegenerative Diseases, Tübingen (D))

Aβ1-42-test (Ruhr University (D))

Proteome-test(Kings College, London (UK))

IRS-1-test(UCSF Geriatric Research Center, San Francisco (USA))

microRNA-test(University of Otago, Otago (NZ))

Based on genetic risk factors (<5% of the Alzheimer’s cases)

Diagnostic microRNA kit(Amoneta Diagnostics (F))

TGS test

APOE4-test(LabCorp, USA)

A genetic non-diagnostic test

Competive advantages

✓ Test predicting non-genetic Alzheimer’s potential before irreversible brain damage

occurred

✓ Addressing the urgent need of patients organizations, medical staff, society and

industry

✓ Manageable weaknesses and threats

Mild to severe

irreversible brain

damange

No irreversible

brain damange